title: Type II radical hysterectomy and adjuvant therapy for pelvic lymph node metastasis with stage IB-IIB cervical carcinoma: a retrospective study of 288 patients.
abstract: OBJECTIVE
  The aim of this study was to evaluate type II radical hysterectomy with or without adjuvant therapy as a treatment for patients with pelvic lymph node metastasis (PLNM) and stage IB-IIB cervical carcinoma.
  
  
  METHODS
  A total of 288 patients with stage IB-IIB cervical carcinoma and confirmed PLNM who underwent a type II radical hysterectomy between 1995 and 2005 were retrospectively evaluated.
  
  
  RESULTS
  The 5-year overall survival (OS) rate for this cohort was 65.6%, and independent prognostic factors identified for PLNM patients included a non-squamous cell histological subtype and parametrial involvement. Survival differences between patients that received or did not receive adjuvant treatment were also evaluated, and the 5-year OS and DFS rates for patients who did not receive adjuvant therapy (47 and 41.4%, respectively) were much lower than the rates for patients who did receive adjuvant therapies (67.7 and 59.4%, respectively). However, these differences were not statistically significant (OS, P = 0.057; DFS, P = 0.080).
  
  
  CONCLUSIONS
  Type II radical hysterectomy, in combination with adjuvant therapies, is an efficient treatment for PLNM patients with stage IB-IIB cervical cancer.
authors.affiliation: State Key Laboratory of Oncology in Southern China, Guangzhou, Guangdong PR China. zheng_min_2006@yahoo.com.cn
authors.forename: Min
authors.initials: M
authors.lastname: Zheng
authors.forename: Long
authors.initials: L
authors.lastname: Huang
authors.forename: Ji-Hong
authors.initials: JH
authors.lastname: Liu
authors.forename: Ying
authors.initials: Y
authors.lastname: Xiong
authors.forename: Jun-Dong
authors.initials: JD
authors.lastname: Li
authors.forename: Xin
authors.initials: X
authors.lastname: Huang
authors.forename: Li
authors.initials: L
authors.lastname: He
authors.forename: Yu-Feng
authors.initials: YF
authors.lastname: Ren
authors.forename: Hui-Yun
authors.initials: HY
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D001918:Brachytherapy; D002294:Carcinoma, Squamous Cell / Q000556:secondary / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D007069:Ifosfamide / Q000008:administration & dosage; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D010386:Pelvic Neoplasms / Q000556:secondary / Q000628:therapy*; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000628:therapy*; D055815:Young Adult
chemical_list: D001761:Bleomycin; D017239:Paclitaxel; D002945:Cisplatin; D005472:Fluorouracil; D007069:Ifosfamide